Cat. No.: HY-B0144

Pitavastatin Calcium

(Synonyms: NK-104 hemicalcium; Pitavastatin hemicalcium)

12 Cited Publications

Customer Review

Based on 12 publication(s) in Google Scholar

Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.

For research use only. We do not sell to patients.

Purity: 99.89%
CAS No.: 147526-32-7
Formula: C₂₅H₂₃Ca_0.5FNO₄
Molecular Weight:440.49

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Pitavastatin Calcium Chemical Structure

CAS No.: 147526-32-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

HMG-CoA Reductase^[1]

In Vitro

Pitavastatin Calcium inhibits the growth of a panel of ovarian cancer cells, including those considered most likely to represent HGSOC, grown as a monolayers (IC₅₀ = 0.4-5 μM) or as spheroids (IC₅₀=0.6-4 μM)^[3].
Pitavastatin Calcium (1 μM; 48 hours ) induces apoptosis, evidenced by the increased activity of executioner caspases-3,7 as well as caspase-8 and caspase-9 in Ovcar-8 cells and Ovcar-3 cells^[3].
Pitavastatin (1 μM, 48 hours) causes PARP cleavage in Ovcar-8 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

Ovcar-8 cells
Concentration:

1 μM
Incubation Time:

48 hours
Result:

Induced PARP cleavage.

In Vivo

Pitavastatin Calcium (59 mg/kg; p.o.; twice daily for 28 days) causes significant tumour regression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4 week old female NCR Nu/Nu female mice (bearing Ovcar-4 tumours)^[3]
Dosage:

59 mg/kg
Administration:

p.o.; twice daily for 28 days
Result:

Caused significant tumour regression.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 147526-32-7
Appearance Solid
Molecular Weight 440.49
Formula C₂₅H₂₃Ca_0.5FNO₄
Color White to off-white
SMILES

O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4.[0.5Ca2+]
Synonyms

NK-104 hemicalcium; Pitavastatin hemicalcium
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (12)

All PK/PD AnalysisBio/Physico-chemical AssayHistological Imaging/StainingCell Proliferation/Viability AssayMicrobiological AssayIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

J Hepatol

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. [Abstract]

2021 Aug;75(2):363-376. PMID: 33887357
Acta Pharm Sin B

Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease. [Abstract]

2020 May;10(5):850-860. PMID: 32528832

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 May;10(5):850-860. [Abstract]

Pharmacokinetic parameters of Pitavastatin (5 mg/kg; single dose) after oral administration.

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 May;10(5):850-860. [Abstract]

Pharmacokinetics of Pitavastatin (5 mg/kg; p.o.; single dose) in WT and KO rats. The concentrations of Pitavastatin were determined by LC–MS/MS.
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Antioxidants (Basel)

Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species. [Abstract]

2024 May 29;13(6):667. PMID: 38929106

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]

Pitavastatin Calcium (0.5-1 μM) makes FLC fungicidal.

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]

PIT (0-25 μM) confers fungicidal properties to voriconazole, ketoconazole, itraconazole, and miconazole.

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]

MIC assays and spotting assays show that erg11△/erg11△ was significantly sensitive to PIT (0-100 μM) compared to the wild-type strain.
Biochem Pharmacol

Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. [Abstract]

2019 Nov:169:113612. PMID: 31437461

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2019 Nov:169:113612. [Abstract]

Uptake ability of Pitavastatin (a human OATP1B1/1B3 substrate，0.1-10 μM; 1 h) by the control and rSlco1b2 overexpression cells. The rate was expressed as the relative intracellular substrate concentration (substrate/internal standard MS/MS response ratio).
Bioorg Chem

Dried tangerine peel polysaccharide (DTPP) alleviates hepatic steatosis by suppressing TLR4/MD-2-mediated inflammation and endoplasmic reticulum stress. [Abstract]

2024 Jun:147:107369. PMID: 38640721

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Bioorg Chem. 2024 Jun:147:107369. [Abstract]

Oil red O staining and quantification of zebrafish liver after treatment with DTPP and Pitavastatin Calcium. Day1 of DTPP treatment.

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Bioorg Chem. 2024 Jun:147:107369. [Abstract]

Oil red O staining and quantification of zebrafish liver after treatment with DTPP and Pitavastatin Calcium. Day3 of DTPP treatment.
FASEB J

2026 May 15;40(9):e71873. PMID: 42087353
Proteomics

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]

2023 Aug;23(16):e2300041. PMID: 37140101

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Proteomics. 2023 Aug;23(16):e2300041. [Abstract]

IC₅₀ values of ERK, S6K inhibitors and statins in parental and resistant cells. (The treatment duration for compounds such as Pitavastatin was 72 h.)

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Proteomics. 2023 Aug;23(16):e2300041. [Abstract]

Western blot against cav-1 after treatment of resistant cells with statins at IC₅₀s for 48 h. Stained MIA PaCa-2 cells were treated with 1 µM GDC-0994, 30 µM DG2, 1.56 µM atorvastatin, 1.56 µM fluvastatin or 0.195 µM Pitavastatin.
Acta Biochim Biophys Sin (Shanghai)

Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis. [Abstract]

2024 Apr 25;56(4):621-633. PMID: 38516704

Pitavastatin Calcium purchased from MedChemExpress. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):621-633. [Abstract]

Typical oil red O staining images showing the alleviation of lipid accumulation by LMY and Pitavastatin (NK-104) (2% (w/w); dietary administration) in larval zebrafish. The number of zebrafish larvae involved in each experimental group is indicated in the top left corner of each image.
Braz J Med Biol Res

Pitavastatin reduces intestinal fibrosis in chronic colitis and inhibits colon fibroblast activation by enhancing MMP-9 expression via the IGF-1/IGF-1R pathway. [Abstract]

2025 Aug 22:58:e14540. PMID: 40862456
bioRxiv

2024 June 11.
Research Square Preprint

2024 Apr 9.

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (113.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2702 mL

11.3510 mL

22.7020 mL

5 mM

0.4540 mL

2.2702 mL

4.5404 mL

10 mM

0.2270 mL

1.1351 mL

2.2702 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Mukhtar RY, et al. Pitavastatin. Int J Clin Pract. 2005 Feb;59(2):239-52. [Content Brief]

[2]. Kajinami K, et al. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003 Fall;21(3):199-215. [Content Brief]

[3]. Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27(5):413-24. [Content Brief]

[4]. Hamano T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012 Oct;33(10):2306-20. [Content Brief]

[5]. de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7(1):5410. [Content Brief]

[6]. Demir B, et al. The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. Cardiovasc Ther. 2019 May 2;2019:2549432. [Content Brief]

[7]. Hayashi T, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004 Oct;176(2):255-63. [Content Brief]

[8]. Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021 Nov;84:101127. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2702 mL	11.3510 mL	22.7020 mL	56.7550 mL
	5 mM	0.4540 mL	2.2702 mL	4.5404 mL	11.3510 mL
	10 mM	0.2270 mL	1.1351 mL	2.2702 mL	5.6755 mL
	15 mM	0.1513 mL	0.7567 mL	1.5135 mL	3.7837 mL
	20 mM	0.1135 mL	0.5675 mL	1.1351 mL	2.8377 mL
	25 mM	0.0908 mL	0.4540 mL	0.9081 mL	2.2702 mL
	30 mM	0.0757 mL	0.3784 mL	0.7567 mL	1.8918 mL
	40 mM	0.0568 mL	0.2838 mL	0.5675 mL	1.4189 mL
	50 mM	0.0454 mL	0.2270 mL	0.4540 mL	1.1351 mL
	60 mM	0.0378 mL	0.1892 mL	0.3784 mL	0.9459 mL
	80 mM	0.0284 mL	0.1419 mL	0.2838 mL	0.7094 mL
	100 mM	0.0227 mL	0.1135 mL	0.2270 mL	0.5675 mL

Keywords

Pitavastatin Calcium

12 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Pitavastatin Calcium

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Cancer Metabolism Compound Library

Mitochondria-Targeted Compound Library

Lipid Metabolism Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Pitavastatin Calcium

Biological Activity

Chemical Information

Publications (12)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Pitavastatin Calcium Related Classifications

HY-B0144 Related Classifications